Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 3, 1996, Pages 199-204

  Mogi, Hitoshi ^a   Hasegawa, Yoshinori ^a   Watanabe, Atsushi ^a   Nomura, Futnio ^a   Saka, Hideo ^a   Shimokata, Kaoru ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Irinotecan; Isobologram; Lung cancer; Vinorelbine

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; IRINOTECAN; NAVELBINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCULATION; CARCINOMA CELL; CELL LINE; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SQUAMOUS CELL; STATISTICAL ANALYSIS; TECHNIQUE;

EID: 0031060187     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050560     Document Type: Article

References (24)

1. Berenbaum MC (1977) Synergy, additivism and antagonism in immunosuppression. Clin Exp Immunol 28:1
2. Berenbaum MC (1985) The expected effect of a combination of agents:the general solution. J Theor Biol 114:413
3. Berthaud P, Le Chevalier T, Ruffle P, Baldeyrou P, Arriagada R, Besson F, Tursz T (1992) Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 28A:1863
4. Bliss CI (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26:585
5. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27
6. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC (1989) Efficacy of Navelbine (NVB) in non-small cell lung cancer (NSCLC). Semin Oncol 16:26
7. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC (1991) A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14:115
8. Elion GB, Singer S, Hitchings GH (1954) Antagonists of nucleic acid derivatives: part VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 208:477
9. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer . J Clin Oncol 10:16
10. Ginsberg RJ, Kris MG, Armstrong JG (1993) Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology, 4th edn. JB Lippincott Company, Philadelphia, p 673
11. Gomi K, Ohno H, Nomura K, Okabe M, Kobayashi K, Niitani H (1992) Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture. Jpn J Cancer Res 83:532
12. Greco WR, Bravo G, Parsons AJ (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47:331
13. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715
14. Kano Y, Ohnuma T, Okano T, Holland JF (1988) Effects of vincristine in combination with methotrexatc and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 48:351
15. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50:604
16. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360
17. Loewe S, Muischnek H (1926) Effect of combinations:mathematical basis of problem. Arch Exp Pathol Parmakol 114:313
18. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S (1992) CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775
19. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J Immunol Methods 65:55
20. Pignon JP, Stewart LA, Souhami RL, Arriagada R. (1994) A meta-analysis using individual patient data from randomized clinical trials of chemotherapy in non-small cell lung cancer:(2) survival in the locally advanced setting. Proc Am Soc Clin Oncol 13:334
21. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer report of a Canadian multicenter randomized trial. J Clin Oncol 6:633
22. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP (1993) Polychemotherapy in advanced non small cell lung cancer:a meta-analysis. Lancet 342:19
23. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy:the concept of additivity. Int J Radiat Oncol Biol Phys 5:85
24. Tsai CM, Gazdar AF, Venzon DJ, Steinberg SM, Dedrick RL, Mulshine JL, Kramer BS (1989) Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). Cancer Res 49:2390